Novocure
Dr. Sebastian Oberbeck, PhD, currently serves as the Medical Science Liaison Manager for Novocure, focusing on Glioblastoma treatment in North Germany since May 2022. In addition, Dr. Oberbeck has been a lecturer in Cell Culture and GMP at Rheinische Fachhochschule Köln since March 2020. Previously, Dr. Oberbeck held the position of Senior Scientist in Assay Development at Alvotech and completed postdoctoral research at the University Clinic Bonn. Dr. Oberbeck's academic journey includes a PhD in Molecular Biomedicine from Universitätsklinik Köln, a Master of Science, and a Bachelor of Science, both from Bonn-Rhein-Sieg University of Applied Sciences, with a strong background in cytogenetics and tumor immunology.
This person is not in any offices
Novocure
3 followers
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma.